All In Biotech

Drug Trial Radar · NCT07850765

Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets

sEMa-LIFE: Unveiling Semaglutide's Impact on Daily Life - Patient and Physicians Experience Across Six Emerging Markets

Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

1,260

Actual

Start

Aug 28, 2026

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 30, 2026

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.

Conditions

  • Overweight
  • Obesity

Interventions

  • SemaglutideDrug

    This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Food Noise Questionnaire (FNQ) scoreTime frame: At data capture (Day 1)
  2. Change in Body WeightTime frame: At data capture (Day 1)
  3. Health-Related Quality of Life Measured by EQ-5D-5LTime frame: At data capture (Day 1)
  4. Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)Time frame: At data capture (Day 1)
  5. Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)Time frame: At data capture (Day 1)
  6. Number of Participant Satisfaction With WegovyTime frame: At data capture (Day 1)
  7. Change in Body Mass Index (BMI)Time frame: At data capture (Day 1)
  8. Percent Change in Body WeightTime frame: At data capture (Day 1)
  9. Number of Participants with Achievement of Weight-Loss TargetTime frame: At data capture (Day 1)
  10. Number of Participants who Concern About Future Weight GainTime frame: At data capture (Day 1)
  11. Impact of Wegovy on Weight-Related BurdenTime frame: At data capture (Day 1)
  12. Impact of Wegovy on Daily Life and Health BehavioursTime frame: At data capture (Day 1)

Locations

6 sites in 6 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Jerusalem, Israel

  • Novo Nordisk Investigational Site

    Mexico City, Mexico

  • Novo Nordisk Investigational Site

    Riyadh, Saudi Arabia

  • Novo Nordisk Investigational Site

    Pretoria, South Africa

  • Novo Nordisk Investigational Site

    Ankara, Turkey (Türkiye)

  • Novo Nordisk Investigational Site

    Abu Dhabi, United Arab Emirates

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.